View Older Stories View More Recent Stories

Jan 4, 2021 07:00AM Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
Dec 21, 2020 07:35AM Cyclerion Therapeutics (CYCN) announces Anjeza Gjino promoted to CFO; Cheryl Gault promoted to COO
Dec 21, 2020 07:30AM Cyclerion Announces Leadership Transitions
Dec 21, 2020 07:30AM Cyclerion Announces Leadership Transitions
Nov 5, 2020 07:00AM Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
Nov 5, 2020 07:00AM Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
Oct 14, 2020 07:03AM Cyclerion Therapeutics (CYCN) Reports Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
Oct 14, 2020 07:03AM Cyclerion Therapeutics (CYCN) says Phase 2 STRONG-SCD study results in SCD did not demonstrate adequate activity to support further internal clinical development
Oct 14, 2020 07:01AM Cyclerion Therapeutics (CYCN) Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
Oct 14, 2020 07:00AM Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
Oct 14, 2020 07:00AM Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
Oct 14, 2020 07:00AM Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
Oct 14, 2020 07:00AM Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
Sep 4, 2020 07:00AM Cyclerion to Participate at Upcoming September 2020 Investor Conferences
Sep 4, 2020 07:00AM Cyclerion to Participate at Upcoming September 2020 Investor Conferences
Aug 25, 2020 07:00AM Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
Aug 25, 2020 07:00AM Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
Aug 3, 2020 09:25AM Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
Aug 3, 2020 09:25AM Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
Jul 30, 2020 09:00AM Cyclerion Therapeutics Completes $24 Million Private Placement
Jul 30, 2020 09:00AM Cyclerion Therapeutics Completes $24 Million Private Placement
Jul 17, 2020 07:00AM Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit
Jul 17, 2020 07:00AM Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit
Jun 18, 2020 04:01PM Cyclerion to Host Webcast Investor Event on July 9, 2020
Jun 18, 2020 04:01PM Cyclerion to Host Webcast Investor Event on July 9, 2020
Apr 10, 2020 07:00AM Cyclerion Updates Corporate Progress
Apr 10, 2020 07:00AM Cyclerion Updates Corporate Progress
Jan 13, 2020 07:05AM Cyclerion Therapeutics (CYCN) Reports IW-6463 Phase 1 Study Results that Support Further Development for Neurodegenerative Diseases
Jan 13, 2020 07:00AM Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
Jan 13, 2020 07:00AM Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
Dec 23, 2019 07:00AM Cyclerion to Present at the J.P. Morgan Healthcare Conference
Dec 23, 2019 07:00AM Cyclerion to Present at the J.P. Morgan Healthcare Conference
Nov 27, 2019 07:00AM Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Nov 27, 2019 07:00AM Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Oct 30, 2019 07:40AM Cyclerion Therapeutics (CYCN) Phase 2 Praliciguat study in HFpEF patients did not meet primary endpoint
Oct 30, 2019 07:39AM Cyclerion Therapeutics (CYCN) Praliciguat phase 2 study did not meet statistical significance on its primary endpoint
Oct 30, 2019 07:31AM Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
Oct 30, 2019 07:31AM Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
Oct 30, 2019 07:30AM Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
Oct 30, 2019 07:30AM Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
Oct 8, 2019 08:00AM Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings
Oct 8, 2019 08:00AM Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings
Sep 10, 2019 08:00AM Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17
Sep 10, 2019 08:00AM Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17
Aug 12, 2019 08:00AM Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months
Aug 12, 2019 08:00AM Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months
Jun 11, 2019 08:30AM Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP
Jun 11, 2019 08:30AM Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP
Jun 4, 2019 08:30AM Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings
Jun 4, 2019 08:30AM Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings
View More Recent Stories View Older Stories